These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 24714356

  • 41. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L.
    J Immunol; 2010 Jan 01; 184(1):452-65. PubMed ID: 19949105
    [Abstract] [Full Text] [Related]

  • 42. Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation.
    Rücker-Braun E, Link CS, Schmiedgen M, Tunger A, Vizjak P, Teipel R, Wehner R, Kühn D, Fuchs YF, Oelschlägel U, Germeroth L, Schmitz M, Bornhäuser M, Schetelig J, Heidenreich F.
    Exp Hematol; 2016 Nov 01; 44(11):1024-1033.e1. PubMed ID: 27473564
    [Abstract] [Full Text] [Related]

  • 43. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cells.
    Tomiyama M, Takahara M, Egawa K, Nieda M.
    Anticancer Res; 2004 Nov 01; 24(5C):3327-33. PubMed ID: 15515428
    [Abstract] [Full Text] [Related]

  • 44. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE.
    Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann PV, Anthony DD.
    Cell Immunol; 2005 May 01; 235(1):29-38. PubMed ID: 16181618
    [Abstract] [Full Text] [Related]

  • 45. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.
    Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E, Tellam J, Marlton P, Seymour JF, Gandhi M, Khanna R.
    J Immunol; 2006 Oct 01; 177(7):4897-906. PubMed ID: 16982932
    [Abstract] [Full Text] [Related]

  • 46. Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.
    Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M.
    J Immunother; 2015 Oct 01; 38(2):62-70. PubMed ID: 25658615
    [Abstract] [Full Text] [Related]

  • 47. Telomerase in cancer immunotherapy.
    Liu JP, Chen W, Schwarer AP, Li H.
    Biochim Biophys Acta; 2010 Jan 01; 1805(1):35-42. PubMed ID: 19751801
    [Abstract] [Full Text] [Related]

  • 48. Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.
    Han S, Huang Y, Liang Y, Ho Y, Wang Y, Chang LJ.
    J Hematol Oncol; 2009 Aug 06; 2():34. PubMed ID: 19660111
    [Abstract] [Full Text] [Related]

  • 49. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy.
    Watanabe K, Suzuki S, Kamei M, Toji S, Kawase T, Takahashi T, Kuzushima K, Akatsuka Y.
    Int J Hematol; 2008 Oct 06; 88(3):311-320. PubMed ID: 18677654
    [Abstract] [Full Text] [Related]

  • 50. Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
    Kim S, Sohn HJ, Lee HJ, Sohn DH, Hyun SJ, Cho HI, Kim TG.
    J Immunother; 2017 Apr 06; 40(3):83-93. PubMed ID: 28099196
    [Abstract] [Full Text] [Related]

  • 51. Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.
    Campillo-Davo D, Fujiki F, Van den Bergh JMJ, De Reu H, Smits ELJM, Goossens H, Sugiyama H, Lion E, Berneman ZN, Van Tendeloo V.
    Front Immunol; 2018 Apr 06; 9():2503. PubMed ID: 30464762
    [Abstract] [Full Text] [Related]

  • 52. Isolating cytomegalovirus-specific T cells for adoptive transfer: are we there yet?
    Bollard CM.
    Cytotherapy; 2010 Nov 06; 12(7):857-8. PubMed ID: 20942604
    [No Abstract] [Full Text] [Related]

  • 53. Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.
    Jæhger DE, Hübbe ML, Kræmer MK, Clergeaud G, Olsen AV, Stavnsbjerg C, Wiinholt MN, Kjær A, Henriksen JR, Hansen AE, Andresen TL.
    Sci Rep; 2021 Oct 05; 11(1):19794. PubMed ID: 34611284
    [Abstract] [Full Text] [Related]

  • 54. Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans.
    Zanetti M, Hernandez X, Langlade-Demoyen P.
    Springer Semin Immunopathol; 2005 Jun 05; 27(1):87-104. PubMed ID: 15711953
    [Abstract] [Full Text] [Related]

  • 55. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
    Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM.
    J Immunother; 2008 Sep 05; 31(7):665-74. PubMed ID: 18600178
    [Abstract] [Full Text] [Related]

  • 56. Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancer.
    Forget MA, Reuben A, Turcotte S, Martin J, Lapointe R.
    Cancer Immunol Immunother; 2011 Aug 05; 60(8):1119-25. PubMed ID: 21681374
    [Abstract] [Full Text] [Related]

  • 57. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD, Harris DT, Kranz DM.
    Curr Opin Immunol; 2015 Apr 05; 33():16-22. PubMed ID: 25618219
    [Abstract] [Full Text] [Related]

  • 58. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
    Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, Bo J, Fan H, Zhang Y, Zhang YJ, Chen MX, Feng KC, Wang QS, Fu XB, Han WD.
    Clin Immunol; 2014 Dec 05; 155(2):160-75. PubMed ID: 25444722
    [Abstract] [Full Text] [Related]

  • 59. Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors.
    Choi W, Lee Y, Choi BK, Park BM, Kim YH, Yun T, Lee WJ, Yoo H, Baek JY, Woo SM, Lim MC, Kwon BS.
    Cytotherapy; 2023 Nov 05; 25(11):1236-1241. PubMed ID: 37632518
    [Abstract] [Full Text] [Related]

  • 60. Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy.
    Chamucero-Millares JA, Bernal-Estévez DA, Parra-López CA.
    Cell Immunol; 2021 Feb 05; 360():104257. PubMed ID: 33387685
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.